Tyra Biosciences Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

TYRA$21.00-5.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Stockholders' Equity

(in thousands, except share amounts)

Common Stock · AdditionalPaid-InCapital · Accumulated Other Comprehensive Gain (Loss) · AccumulatedDeficit · TotalStockholders’Equity
Shares · Amount
Balance at December 31, 2022	42,353,550	$4	$353,521	$—	$(95,696)	$257,829
Issuance of common stock under benefit plans	129,669	—	376	—	—	376
Vesting of shares of common stock subject to repurchase	52,155	—	32	—	—	32
Stock-based compensation	—	—	2,433	—	—	2,433
Net loss	—	—	—	—	(11,880)	(11,880)
Balance at March 31, 2023	42,535,374	$4	$356,362	$—	$(107,576)	$248,790
Issuance of common stock under benefit plans	230,502	—	494	—	—	494
Vesting of shares of common stock subject to repurchase	51,357	—	31	—	—	31
Stock-based compensation	—	—	2,529	—	—	2,529
Net loss	—	—	—	—	(13,272)	(13,272)
Balance at June 30, 2023	42,817,233	$4	$359,416	$—	$(120,848)	$238,572
Issuance of common stock under benefit plans	60,763	—	343	—	—	343
Vesting of shares of common stock subject to repurchase	50,888	—	30	—	—	30
Stock-based compensation	—	—	4,377	—	—	4,377
Net loss	—	—	—	—	(21,152)	(21,152)
Balance at September 30, 2023	42,928,884	$4	$364,166	$—	$(142,000)	$222,170

Common Stock · AdditionalPaid-InCapital · Accumulated Other Comprehensive Gain (Loss) · AccumulatedDeficit · TotalStockholders’Equity
Shares · Amount
Balance at December 31, 2023	43,024,634	$4	$368,707	$381	$(164,830)	$204,262
Issuance of common stock under Private Placement, net of issuance costs of $0.2 million	9,286,023	1	120,557	—	—	120,558
Issuance of pre-funded warrants, net of issuance costs of $0.2 million	—	—	79,022	—	—	79,022
Issuance of common stock under benefit plans	135,972	—	484	—	—	484
Vesting of shares of common stock subject to repurchase	27,904	—	17	—	—	17
Stock-based compensation	—	—	4,115	—	—	4,115
Unrealized loss on marketable securities available-for-sale, net	—	—	—	(387)	—	(387)
Net loss	—	—	—	—	(18,192)	(18,192)
Balance at March 31, 2024	52,474,533	$5	$572,902	$(6)	$(183,022)	$389,879
Issuance of common stock under benefit plans	246,887	—	624	—	—	624
Vesting of shares of common stock subject to repurchase	15,038	—	9	—	—	9
Stock-based compensation	—	—	4,411	—	—	4,411
Unrealized loss on marketable securities available-for-sale, net	—	—	—	(178)	—	(178)
Net loss	—	—	—	—	(18,702)	(18,702)
Balance at June 30, 2024	52,736,458	$5	$577,946	$(184)	$(201,724)	$376,043
Issuance of common stock under benefit plans	121,153	—	743	—	—	743
Vesting of shares of common stock subject to repurchase	14,214	—	9	—	—	9
Stock-based compensation	—	—	7,573	—	—	7,573
Unrealized gain on marketable securities available-for-sale, net	—	—	—	1,936	—	1,936
Net loss	—	—	—	—	(24,016)	(24,016)
Balance at September 30, 2024	52,871,825	$5	$586,271	$1,752	$(225,740)	$362,288

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.